Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its optimized,

GlobeNewswireJun 14 15:00

Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?

Yahoo FinanceJun 6 23:31

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella,

GlobeNewswireMay 30 18:30

Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo

Seeking AlphaMay 25 22:24

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report

GlobeNewswireMay 15 04:00

Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)

TipRanksMay 11 09:50